CLOSE X Edit Favorites Enter up to 25 symbols separated by commas or spaces in the text box below. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings? These symbols will be available during your session for use on applicable pages. If, at any time, you are interested in reverting to our default settings, please select Default Setting above.If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com CLOSE X Please confirm your selection: You have selected to change your default setting for the Quote Search.
Non-Hodgkin's lymphoma occurs when the body produces too many abnormal lymphocytes, a type of white blood cell. Jefferies analyst Biren Amin said he expected accelerated approval for the drug from the U.S. Food and Drug Administration by the end of 2017. But Juno said in November that five leukemia patients died due to severe brain swelling, raising concerns about its therapy. Kite said it plans to submit a marketing application for the therapy with European regulators this year. nL2N1C21VL] The company said on Tuesday that its primary analysis included all 101 patients and there were no additional deaths due to adverse events.
Non-Hodgkin Lymphoma occurs when the body produces too many abnormal lymphocytes, a type of white blood cell. A number of drugmakers, including Juno Therapeutics Inc
, Novartis AG and Bluebird Bio Inc , are testing CAR T-cell therapies in various stages of development. CAR T-cell drugs are made by genetically altering a patients' own T-cells to add a component of antibodies that makes them better able to spot and kill cancer cells. Shutterstock photoUPDATE 2-Kite Pharma's cancer drug clears main goal in study* No additional deaths due to adverse events * European application planned for this year * Shares halted; Stock up 27 pct YTD (Adds details) Feb 28 (Reuters) - Kite Pharma Inc said on Tuesday its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin lymphoma, meeting the main goal of a key study. But Juno said in November five leukemia patients died due to severe brain swelling, raising concerns about its therapy.
collected by :Lucy William
To follow all the new news about Health care
No comments:
Post a Comment